Clinical trial NCT04611256: Mesenchymal Stem Cells in Patients Diagnosed With COVID-19
Official title: Adjuvant Therapy With Mesenchymal Stem Cells in Patients Diagnosed With COVID-19 in Critical Condition
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
Conditions: Covid19
Keywords: COVID-19
Adjuvant therapy
mesenchymal stem cells
Mexico
Lead sponsor: Hospital Reg. Lic. Adolfo Lopez Mateos
Sponsor class: OTHER_GOV
Collaborators: name: Instituto de Terapia Celular: ITC
First posted: 2020-11-02
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The propose of this study is implement adjuvant therapy with adipose tissue derived-mesenchymal stem cells (MSCs) for critical COVID-19 patients admitted to the intensive care unit of the Regional Hospital Lic. Adolfo López Mateos of the Institute for Social Security and Services for State Workers to reduce cytokine storm and contribute to the favorable resolution of respiratory insufficiency and multiple organic failure.

Detailed description: Within the epidemic context of phase 3 that currently exists in Mexico, implementation of new treatments that have shown to be beneficial for patients in a critical state in other countries is an urgent need. Adipose tissue derived-mesenchymal stem cells for could favor the regulation of patient immune system to reduce the proinflammatory state and promoting the regeneration of damaged tissues.

Patients diagnosed COVID-19 and confirmed positive with the virus by PCR, will be treated with two intravenous infusions MSCs on the day 1 (D1) and the day 3 (D3) of the treatment consisting of 1X106/kg each.

We will assess the pulmonary lesion area by chest x-ray or computed axial tomography at baseline and days 2, 3, 5, 10, 15, 20, and 25.

Days to clinical improvement (to be evaluated on days 2, 3, 5, 10, 15, 20, 25), considering temperature and other vital signs measurement, arterial oxygen saturation, blood chemistry (including liver function tests), creatine phosphokinase, C reactive protein, immune cells (CD3+, CD4+, CD8+, CD16+, CD19+, and CD56+ lymphocytes), pro-inflammatory cytokines (IL-1β, IL- 2, TNF-α, ITN-γ, IL-4, IL-6, IL-10), immunoglobulins (IgA, IgG, IgM, and IgE), HLA profile expression, and weaning from mechanical ventilation.

Eligibility criteria: Inclusion Criteria:

* Aged between 18 and 65.
* RT-PCR positive for SARS-CoV-2 (Berlin protocol).
* Moderate to severe acute respiratory insufficiency (100 mmHg \<PaO2/FiO2 ≤ 200 mmHg).
* Confirmatory diagnosis of pulmonary injury by chest teleradiography or computed axial t tomography.
* Being under standard therapy for COVID-19.
* Informed consent signed by the patient or a legally acceptable representative (in the case of the legal representative, informed consent could be obtained by a phone call or email with the subsequent written confirmation).

Exclusion Criteria:

* Reserved prognosis (survival expected by the physician of fewer than three days).
* Being under immunosuppressive drug treatment.
* Severe kidney failure (estimated glomerular filtration rate \< 30 ml/min) or under continuous kidney replacement therapy, hemodialysis, or peritoneal dialysis.
* Immunosuppressed patients (except when the cause is corticosteroid treatment).
* Pregnant or lactating women.
* Patients who plan to become pregnant during the study period or within six months after the end of the study period.
* Participation in another clinical trial with an experimental drug during the last 30 days.
* Pathologies that in medical judgment constitute a contraindication to participate in the study.

Primary outcomes:
measure: Change form baseline in Arterial oxygen saturation
timeFrame: up to 25 days
measure: Change form baseline in Arterial oxygen saturation
timeFrame: up to 25 days
measure: Days to clinical improvement
timeFrame: up to 25 days
Secondary outcomes:
measure: Change Form Baseline in C reactive protein at 25 days
timeFrame: up to 25 days
measure: Change Form Baseline Immune cells: CD3+, CD4+, CD8+, CD16+, CD19+, and CD56+ lymphocytes
timeFrame: up to 25 days
measure: Change Form Baseline in pro-inflammatory cytokines: IL-1β, IL- 2, TNF-α, ITN-γ, IL-4, IL-6, IL-10
timeFrame: up to 25 days
measure: Change Form Baseline in Immunoglobulins; IgA, IgG, IgM, and IgE.
timeFrame: up to 25 days
Other outcomes:
Locations:
city: Mexico City
country: Mexico
facility: Hospital Regional Lic Adolfo Lopez Mateos
state: Ciudad De Mexico CDMX (Mexico City)
Study officials:
References: